{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360016866459014144.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1177/135965350701200816"}},{"identifier":{"@type":"URI","@value":"https://journals.sagepub.com/doi/pdf/10.1177/135965350701200816"}}],"dc:title":[{"@value":"Long-Term Lamivudine Therapy Reduces the Risk of Long-Term Complications of Chronic Hepatitis B Infection even in Patients without Advanced Disease"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:sec><jats:title>Background</jats:title><jats:p> Long-term effects of lamivudine treatment on chronic hepatitis B patients without advanced disease remain unknown. Our aim was to investigate the effects of long-term lamivudine treatment and lamivudine-resistant virus (YMDD) on the development of cirrhosis and hepatocellular carcinoma (HCC) in asymptomatic patients without advanced disease. </jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p> One hundred and forty-two hepatitis B e antigen (HBeAg)-positive patients (median age: 33.9 years) on long-term lamivudine (median treatment duration: 89.9 months) and 124 HBeAg-positive controls (median age: 33.4 years) were prospectively followed up. Patients were monitored for the development of cirrhosis and HCC, liver biochemistry, hepatitis B virus (HBV) DNA levels, HBeAg seroconversion and hepatitis flares. YMDD mutations (YMDD-MT) were determined annually. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> Lamivudine-treated patients had a significantly lower cumulative rate of development of cirrhosis and/or HCC compared with controls ( P=0.005). YMDD-MT occurred in 76.3% of patients after 8 years of lamivudine treatment. When compared with controls and patients with YMDD-MT, patients without YMDD-MT had the greatest reduction of HBV DNA and bilirubin levels, slowest decline of albumin level, highest rate of HBeAg seroconversion and lowest risk of hepatitis flare. Patients with YMDD-MT still had a lower risk for developing cirrhosis and/or HCC ( P=0.024) and a greater HBV DNA reduction ( P=0.001) in comparison with controls. Patients with YMDD-MT and controls had a similar chance of hepatitis flares and hepatic decompensation. </jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p> Long-term lamivudine treatment was associated with a reduced chance of developing cirrhosis and HCC in patients without advanced disease. Although YMDD-MT reduced the benefits from lamivudine therapy, the outcome of these patients was still better than untreated patients. </jats:p></jats:sec>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380016866459014150","@type":"Researcher","foaf:name":[{"@value":"Man-Fung Yuen"}],"jpcoar:affiliationName":[{"@value":"Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong"}]},{"@id":"https://cir.nii.ac.jp/crid/1380016866459014149","@type":"Researcher","foaf:name":[{"@value":"Wai-Kay Seto"}],"jpcoar:affiliationName":[{"@value":"Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong"}]},{"@id":"https://cir.nii.ac.jp/crid/1380016866459014148","@type":"Researcher","foaf:name":[{"@value":"Danny Hoi-Fan Chow"}],"jpcoar:affiliationName":[{"@value":"Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong"}]},{"@id":"https://cir.nii.ac.jp/crid/1380016866459014153","@type":"Researcher","foaf:name":[{"@value":"Kit Tsui"}],"jpcoar:affiliationName":[{"@value":"Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong"}]},{"@id":"https://cir.nii.ac.jp/crid/1380016866459014147","@type":"Researcher","foaf:name":[{"@value":"Danny Ka-Ho Wong"}],"jpcoar:affiliationName":[{"@value":"Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong"}]},{"@id":"https://cir.nii.ac.jp/crid/1380016866459014152","@type":"Researcher","foaf:name":[{"@value":"Vincent Wing-Shun Ngai"}],"jpcoar:affiliationName":[{"@value":"Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong"}]},{"@id":"https://cir.nii.ac.jp/crid/1380016866459014151","@type":"Researcher","foaf:name":[{"@value":"Benjamin Chun-Yu Wong"}],"jpcoar:affiliationName":[{"@value":"Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong"}]},{"@id":"https://cir.nii.ac.jp/crid/1380016866459014146","@type":"Researcher","foaf:name":[{"@value":"James Fung"}],"jpcoar:affiliationName":[{"@value":"Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong"}]},{"@id":"https://cir.nii.ac.jp/crid/1380016866459014144","@type":"Researcher","foaf:name":[{"@value":"John Chi-Hang Yuen"}],"jpcoar:affiliationName":[{"@value":"Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong"}]},{"@id":"https://cir.nii.ac.jp/crid/1380016866459014145","@type":"Researcher","foaf:name":[{"@value":"Ching-Lung Lai"}],"jpcoar:affiliationName":[{"@value":"Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"13596535"},{"@type":"EISSN","@value":"20402058"}],"prism:publicationName":[{"@value":"Antiviral Therapy"}],"dc:publisher":[{"@value":"SAGE Publications"}],"prism:publicationDate":"2007-11","prism:volume":"12","prism:number":"8","prism:startingPage":"1295","prism:endingPage":"1304"},"reviewed":"false","dc:rights":["https://journals.sagepub.com/page/policies/text-and-data-mining-license"],"url":[{"@id":"https://journals.sagepub.com/doi/pdf/10.1177/135965350701200816"}],"createdAt":"2022-04-14","modifiedAt":"2025-03-03","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360004231259057280","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Effects of antiviral therapy on long‐term outcome after liver resection for hepatitis B virus‐related hepatocellular carcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285714965416192","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Antiviral therapy for chronic hepatitis B: Combination of nucleoside analogs and interferon"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567180140804864","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Impact of peginterferon alpha‐2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567181466116736","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Effects of long-term entecavir treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848664562973056","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Management of hepatitis B virus infection during treatment for hepatitis B virus-related hepatocellular carcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001206447135488","@type":"Article","resourceType":"other","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"7. Cutting Edge of the Treatment for Viral Hepatitis"},{"@language":"ja","@value":"7．ウイルス性肝炎の治療の進歩"},{"@value":"教育講演 ウイルス性肝炎の治療の進歩"},{"@language":"ja-Kana","@value":"キョウイク コウエン ウイルスセイ カンエン ノ チリョウ ノ シンポ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679847528832","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Rescue Therapy for Lamivudine-resistant Chronic Hepatitis B: Adefovir Monotherapy, Adefovir Plus Lamivudine or Entecavir Combination Therapy"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1177/135965350701200816"},{"@type":"CROSSREF","@value":"10.1007/s12072-015-9647-8_references_DOI_TuELghyhQCkPpgFmmc8OmRlTWSm"},{"@type":"CROSSREF","@value":"10.1007/s00534-011-0489-z_references_DOI_TuELghyhQCkPpgFmmc8OmRlTWSm"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_TuELghyhQCkPpgFmmc8OmRlTWSm"},{"@type":"CROSSREF","@value":"10.2169/naika.101.2681_references_DOI_TuELghyhQCkPpgFmmc8OmRlTWSm"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_TuELghyhQCkPpgFmmc8OmRlTWSm"},{"@type":"CROSSREF","@value":"10.1002/jmv.23564_references_DOI_TuELghyhQCkPpgFmmc8OmRlTWSm"},{"@type":"CROSSREF","@value":"10.3748/wjg.v21.i27.8249_references_DOI_TuELghyhQCkPpgFmmc8OmRlTWSm"},{"@type":"CROSSREF","@value":"10.4254/wjh.v7.i23.2427_references_DOI_TuELghyhQCkPpgFmmc8OmRlTWSm"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.51.7329_references_DOI_TuELghyhQCkPpgFmmc8OmRlTWSm"}]}